Upregulation of the lysosomal pathway NAADP/TPC2 as a druggable target in focal ischemia

The knowledge on the molecular mechanisms underlying ischemic tolerance due to ischemic preconditioning (IPC) -a sub-lethal ischemic insult-may be useful to dissect new putative druggable targets in stroke therapy. Preclinically, IPC activates a complex cascade of events leading to a preservation of ionic homeostasis and vital functions of organelles, including mitochondria and endoplasmic reticulum. Recently, the involvement of lysosomes as calcium (Ca 2+ ) stores able to modulate dysfunctional autophagy has been highlighted in focal ischemia pathogenesis, thereby opening new possibilities of intervention. Accordingly, hyperfunctional autophagy may be correlated to TPC2 ( Two-Pore Channel 2 ) lysosomal channel, whose inhibition increases neuronal survival rate under hypoxic conditions and reduces ischemic brain volume in rats subjected to focal ischemia. Given the relevant role of NAADP as unique endogenous ligand triggering TPC2-dependent Ca 2+ release, we tested the hypothesis that NAADP/TPC2 signalling could be dysfunctional in focal ischemia and may be restored by IPC. Here we showed that in rat primary cortical neurons exposed to oxygen and glucose deprivation followed by reoxygenation (OGD/Rx) preceded or not by IPC: (1) NAADP level significantly increased during the OGD/Rx but was restored by IPC; (2) NAADP and its mimetic analogue TPC2-A1-N reverted the neuroprotective effect of IPC in hypoxic neurons; (3) NAADP, as well as the tricyclic antidepressant clomipramine and the antipsychotic chlorpromazine, acting as TPC2 agonists, exacerbated cell death in OGD/Rx, while siTPC2, Ned-19 and fluphenazine, by inhibiting TPC2, significantly reduced cell death under the same hypoxic conditions. Furthermore, plasma level of NAADP and TPC2 tissue expression increased in rats subjected to focal ischemia, but they were restored in preconditioned animals. Intravenous administration of the NAADP mimetic analogue TPC2-A1-N counteracted IPC-induced ischemic tolerance in rats subjected to tMCAO. Collectively these data showed that NAADP/TPC2 signaling became dysfunctional, and therefore targetable, in stroke and that NAADP might be considered as a new putative biomarker of the disease.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-16
DOI
https://doi.org/10.3389/fphar.2026.1919869
Primary Topic
Calcium signaling and nucleotide metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Upregulation of the lysosomal pathway NAADP/TPC2 as a druggable target in focal ischemia

Antonella Scorziello, Anna Pannaccione, Tiziano Serfilippi, Valentina Tedeschi et al.
Frontiers in Pharmacology
Calcium signaling and nucleotide metabolism
article

Upregulation of the lysosomal pathway NAADP/TPC2 as a druggable target in focal ischemia

Antonella Scorziello, Anna Pannaccione, Tiziano Serfilippi, Valentina Tedeschi, Raffaella Ciancio, Antonio Vinciguerra, Silvia Piccirillo, Agnese Secondo, Alessandra Preziuso, Valentina Terenzi
article en

Abstract

The knowledge on the molecular mechanisms underlying ischemic tolerance due to ischemic preconditioning (IPC) -a sub-lethal ischemic insult-may be useful to dissect new putative druggable targets in stroke therapy. Preclinically, IPC activates a complex cascade of events leading to a preservation of ionic homeostasis and vital functions of organelles, including mitochondria and endoplasmic reticulum. Recently, the involvement of lysosomes as calcium (Ca 2+ ) stores able to modulate dysfunctional autophagy has been highlighted in focal ischemia pathogenesis, thereby opening new possibilities of intervention. Accordingly, hyperfunctional autophagy may be correlated to TPC2 ( Two-Pore Channel 2 ) lysosomal channel, whose inhibition increases neuronal survival rate under hypoxic conditions and reduces ischemic brain volume in rats subjected to focal ischemia. Given the relevant role of NAADP as unique endogenous ligand triggering TPC2-dependent Ca 2+ release, we tested the hypothesis that NAADP/TPC2 signalling could be dysfunctional in focal ischemia and may be restored by IPC. Here we showed that in rat primary cortical neurons exposed to oxygen and glucose deprivation followed by reoxygenation (OGD/Rx) preceded or not by IPC: (1) NAADP level significantly increased during the OGD/Rx but was restored by IPC; (2) NAADP and its mimetic analogue TPC2-A1-N reverted the neuroprotective effect of IPC in hypoxic neurons; (3) NAADP, as well as the tricyclic antidepressant clomipramine and the antipsychotic chlorpromazine, acting as TPC2 agonists, exacerbated cell death in OGD/Rx, while siTPC2, Ned-19 and fluphenazine, by inhibiting TPC2, significantly reduced cell death under the same hypoxic conditions. Furthermore, plasma level of NAADP and TPC2 tissue expression increased in rats subjected to focal ischemia, but they were restored in preconditioned animals. Intravenous administration of the NAADP mimetic analogue TPC2-A1-N counteracted IPC-induced ischemic tolerance in rats subjected to tMCAO. Collectively these data showed that NAADP/TPC2 signaling became dysfunctional, and therefore targetable, in stroke and that NAADP might be considered as a new putative biomarker of the disease.

Frontiers in PharmacologyVol. 17
Marche Polytechnic University (IT), University of Naples Federico II (IT)
Good health and well-being
Calcium signaling and nucleotide metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon